Acrivon Therapeutics Common Stock Price Prediction
| ACRV Stock | 9.50 0.32 3.26% |
Oversold Vs Overbought
67
Oversold | Overbought |
Acrivon Therapeutics stock price prediction is an act of determining the future value of Acrivon Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Acrivon Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Acrivon Therapeutics and does not consider all of the tangible or intangible factors available from Acrivon Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Acrivon Therapeutics Common, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Acrivon Therapeutics' stock price prediction:EPS Estimate Next Quarter (0.79) | EPS Estimate Current Year (3.11) | EPS Estimate Next Year (3.02) | Wall Street Target Price 19.44 | EPS Estimate Current Quarter (0.73) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Acrivon Therapeutics based on different types of headlines from major news networks to social media. The Acrivon stock price prediction module provides an analysis of price elasticity to changes in media outlook on Acrivon Therapeutics over a specific investment horizon. Using Acrivon Therapeutics hype-based prediction, you can estimate the value of Acrivon Therapeutics Common from the perspective of Acrivon Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Acrivon Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Acrivon Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Acrivon because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Acrivon Therapeutics after-hype prediction price | USD 8.87 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Acrivon |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acrivon Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acrivon Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Acrivon Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Acrivon Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Acrivon Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Acrivon Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Acrivon Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Acrivon Therapeutics' historical news coverage. Acrivon Therapeutics' after-hype downside and upside margins for the prediction period are 0.44 and 19.72, respectively. We have considered Acrivon Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Acrivon Therapeutics is relatively risky at this time. Analysis and calculation of next after-hype price of Acrivon Therapeutics is based on 3 months time horizon.
Acrivon Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Acrivon Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acrivon Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Acrivon Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.96 | 10.85 | 0.63 | 0.47 | 8 Events / Month | 3 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
9.50 | 8.87 | 6.63 |
|
Acrivon Therapeutics Hype Timeline
Acrivon Therapeutics is presently traded for 9.50. The entity has historical hype elasticity of -0.63, and average elasticity to hype of competition of -0.47. Acrivon is projected to decline in value after the next headline, with the price expected to drop to 8.87. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -6.63%, whereas the daily expected return is presently at 1.96%. The volatility of related hype on Acrivon Therapeutics is about 4520.83%, with the expected price after the next announcement by competition of 9.03. About 18.0% of the company shares are held by company insiders. The book value of Acrivon Therapeutics was presently reported as 5.38. The company recorded a loss per share of 2.74. Acrivon Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out Acrivon Therapeutics Basic Forecasting Models to cross-verify your projections.Acrivon Therapeutics Related Hype Analysis
Having access to credible news sources related to Acrivon Therapeutics' direct competition is more important than ever and may enhance your ability to predict Acrivon Therapeutics' future price movements. Getting to know how Acrivon Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Acrivon Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TERN | Terns Pharmaceuticals | (0.75) | 8 per month | 5.23 | (0.01) | 8.64 | (8.38) | 27.76 | |
| AMLX | Amylyx Pharmaceuticals | 0.04 | 6 per month | 0.00 | (0.15) | 6.96 | (8.30) | 103.39 | |
| ABOS | Acumen Pharmaceuticals | 0.1 | 7 per month | 0.00 | (0.02) | 7.28 | (5.98) | 23.58 | |
| INZY | Inozyme PharmaInc | (0.35) | 8 per month | 4.39 | (0.0005) | 8.83 | (8.42) | 25.32 |
Acrivon Therapeutics Additional Predictive Modules
Most predictive techniques to examine Acrivon price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Acrivon using various technical indicators. When you analyze Acrivon charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Acrivon Therapeutics Predictive Indicators
The successful prediction of Acrivon Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Acrivon Therapeutics Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Acrivon Therapeutics based on analysis of Acrivon Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Acrivon Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Acrivon Therapeutics's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 34.46 | 19.61 | 9.75 | 13.32 | Net Debt To EBITDA | 5.82 | 0.75 | 0.47 | 0.45 |
Story Coverage note for Acrivon Therapeutics
The number of cover stories for Acrivon Therapeutics depends on current market conditions and Acrivon Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Acrivon Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Acrivon Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Acrivon Therapeutics Short Properties
Acrivon Therapeutics' future price predictability will typically decrease when Acrivon Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Acrivon Therapeutics Common often depends not only on the future outlook of the potential Acrivon Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acrivon Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.1 M | |
| Cash And Short Term Investments | 127.5 M |
Check out Acrivon Therapeutics Basic Forecasting Models to cross-verify your projections. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.